echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Facilitating standardized diagnosis and treatment of chronic diseases

    Facilitating standardized diagnosis and treatment of chronic diseases

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    After launching the "420 Gout Day" for the first time in 2016, Wanbang Pharmaceutical has never stopped in calling on the public to increase their awareness and attention to hyperuricemia and gout diseases.


    On April 20th, hosted by Wanbang Pharmaceutical, the Gout Professional Committee of the Rheumatology and Immunology Physician Branch of the Chinese Medical Doctor Association, and the Gout Group of the Rheumatology and Immunity Branch of the Cross-Strait Medical and Health Exchange Association, the "Cure Gout, Focus on Chronic Disease Management" activity was held in conjunction .


    The standardized diagnosis and treatment rate for hundreds of millions of people is less than 30%

    The standardized diagnosis and treatment rate for hundreds of millions of people is less than 30%

    With the changes in diet and life>The disease used to occur in people over 40 years old, but now it is becoming younger and more common.


    In sharp contrast to the high prevalence, the public still doesn't know much about the "invisible killer" of hyperuricemia.


    The warning line of uric acid is 420μmol/L.


    Hyperuricemia requires long-term management, diagnosis and treatment

    Hyperuricemia requires long-term management, diagnosis and treatment

    Professor Zou Hejian further pointed out that gout is more than just joint pain.


    In terms of therapeutic drugs, after 40 years after the world’s first-generation anti-gout drug allopurinol was on the market, the US FDA was the first drug approved for the treatment of gout and hyperuric acid.


    In April 2020, the 40mg and 80mg febuxostat tablets (trade name: Youlitong®), a subsidiary of Fosun Pharma's subsidiary Wanbang Pharmaceutical, passed the consistency evaluation of generic drugs, becoming the first company to pass the evaluation; September of the same year , The 20mg specification of the drug has also passed the consistency evaluation of generic drugs, and it is also the first domestic approval.


    According to related studies, starting with a small dose of febuxostat and increasing the dose slowly can help reduce the risk of gout attacks induced by a rapid decrease in blood uric acid levels at the initial stage of uric acid-lowering treatment.


    "As the first company to pass the drug consistency evaluation of febuxostat, the company always adheres to the value proposition of providing patients with high-quality and accessible drugs, in order to benefit more patients.


    In the future, Wanbang Pharmaceutical will continue to actively assume social responsibilities and carry out more public welfare diagnosis and treatment, disease science popularization and other activities with health care as the core, so as to bring the most affectionate health protection for every patient and family, and help more families enjoy themselves.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.